Association d'Aide aux Victimes d'ENDOXAN Cyclophosphamide
Abonné·e de Mediapart

9 Billets

0 Édition

Lien 4 déc. 2019


Pensez-vous que l'ANSM contrôle la qualité des anticancéreux et solutés injectables sur le marché français depuis plus de 30 ans?

Association d'Aide aux Victimes d'ENDOXAN Cyclophosphamide
Abonné·e de Mediapart

Ce blog est personnel, la rédaction n’est pas à l’origine de ses contenus.


It is something we've all heard before: Generic drugs are the same as brand-name drugs. They contain the same active ingredients and their manufacturers are supposed to prove they work the same way as the brand-name counterparts. Many of those generics come from abroad, though, with 80 percent of active ingredients and 40 percent of finished drugs coming from outside the U.S.

But are all of those drugs manufactured overseas really the same?

When CBS News' Anna Werner met Cedric Brown, he was in the hospital for a foot infection – a big improvement from seven years prior when his heart failed and he underwent a transplant. The operation was a success, but months later Brown's condition deteriorated, and he went back to the Cleveland Clinic, where Dr. Randall Starling found Brown's body was rejecting his new heart. Starling discovered that the brand-name anti-rejection drug Brown had been taking, called Prograf, had been switched for a generic manufactured in India.

When Starling looks at the bottle, he "immediately" has questions because that particular drug is on a list of generic medications his hospital tries to avoid prescribing to its patients. The FDA said "a generic medicine is the same as a brand-name medicine in dosage, safety … and quality." But experts at the Cleveland Clinic have determined some generics aren't a close-enough match for their comfort – that even a small variance in the drug may pose serious risks for some patients.

"In a given patient that's high-risk for rejection, there may be no leeway whatsoever," Starling said.

Brown said as soon as he switched back to the brand-name drug, things got much better. But what he went through is a window into a larger problem, according to investigative journalist Katherine Eban, who said she's been looking into this issue for the past five years.

Eban is the author of a book called "Bottle Of Lies." She said that the problem is that the U.S. relies on information submitted by drugmakers in order to approve their generic medications, but some overseas manufacturers aren't being honest.

"There are many companies in the industry that are falsifying their data," Eban said. "Straight out fraud."

The first major fraud case came to light 14 years ago, involving Indian generic manufacturer Ranbaxy. The company paid a half-billion-dollar penalty as part of a 2013 settlement for selling "adulterated drugs" and making "fraudulent statements to the FDA." Former Ranbaxy executive Dinesh Thakur was the whistleblower on the case. He said Ranbaxy isn't alone.

Asked if they are the poster child for how bad things can get, he said, "I wish I could say that. I've seen similar behavior in other companies since 2013."

Eban said a major part of the problem is the FDA's efforts to regulate overseas drug production.

"Our entire drug supply has changed," Eban said. "Now these drugs are overseas and the FDA is forced to be a global agency. So the question is, is it up to the task or not?"

"And how well is that going for them did you find?" Werner asked.

"Very badly," Eban said.

She said that, while FDA inspectors in the U.S. often show up at plants unannounced – overseas, companies are frequently warned weeks in advance that inspectors are coming.

"These inspections that are taking place overseas are essentially staged inspections," Eban said. "They're staged by the companies."

The FDA told CBS News in a statement that it "inspects all brand-name and generic manufacturing facilities around the world" and said it's "conducted a number of unannounced inspections at foreign" plants when the agency has "information from a whistleblower or when the FDA is investigating a drug safety issue." But a former FDA investigator told CBS News when he and others dug deeper into the records at those companies, they found serious problems including fraud.

Reports he and other inspectors filed show they found numerous generic drugmakers falsifying records, covering up manufacturing problems and attempting to hide poor test results. Because of what he said they found, he "would question the safety and efficacy of those drugs."

The FDA said it's "modernized" its "policies" in recent years and that "Americans can be confident in the quality of the products the FDA approves." But those inspection reports came as unwelcome news to Dr. Starling.

"My initial reaction is anger," he said. "To falsify information … to manufacture and make a profit on a drug is just unconscionable to believe that that could happen."

The group that represents generic drugmakers disagrees. It said the industry is contributing hundreds of millions of dollars to help the FDA increase the frequency of inspections. And it notes, "if there are issues going undetected by the FDA there would be severe health issues in this country."

One of the problems here is the lack of public information if you're curious about where your medication is coming from. You can ask your pharmacist which company made your generic medication, but you'll have to do some research to figure out whether that company has ever had to recall products or has been found to have manufacturing issues. And it's difficult – if not impossible – to find out where the companies actually make each drug. The FDA says that's considered "confidential information" under federal law.

Full statement from Dr. Janet Woodcock, director of FDA's Center for Drug Evaluation and Research:

"Protecting patients is the highest priority of the FDA, and Americans can be confident in the quality of the products the FDA approves. Our standards require that brand-name and generic medications have the same intended use and perform the same way in the human body, and we take multiple steps to ensure that generics are just as safe and effective as their brand-name counterparts. Whether a drug is made in the U.S. or overseas, manufacturers must undergo the same, rigorous application process, and the information must be fully reviewed by our highly-trained scientific staff. The FDA inspects all brandname and generic manufacturing facilities around the world, which manufacture product for the U.S. market, to confirm they meet FDA's requirements for manufacturing process. As drug manufacturing has globalized over the years, we have modernized our policies to ensure that companies – regardless of where they are located –meet the FDA's strict standards for producing medicines for U.S. patients that are high quality, safe and effective. The FDA's global inspection efforts focus on higher risk facilities to prevent, uncover and combat data integrity issues and manufacturing problems. Using a risk-based site selection surveillance inspection model, we prioritize domestic and foreign inspections based on multiple factors carefully selected to appropriately target our resources. Over the past several years, we have conducted a number of unannounced inspections at foreign manufacturing facilities – a critical approach when we have information from a whistleblower or when the FDA is investigating a drug safety issue. We also monitor reports from industry, patients, and healthcare providers to identify and resolve potential quality problems. We will remain vigilant in addressing potential issues in the global drug supply chain, in order to make sure Americans have confidence in the safety and quality of their medicines."

© 2019 CBS Interactive Inc. All Rights Reserved.

Bienvenue dans le Club de Mediapart

Tout·e abonné·e à Mediapart dispose d’un blog et peut exercer sa liberté d’expression dans le respect de notre charte de participation.

Les textes ne sont ni validés, ni modérés en amont de leur publication.

Voir notre charte

À la Une de Mediapart

Journal — International
Comment les Chinois ont corrompu les Kabila pour un contrat minier géant
Une société-écran, alimentée par deux sociétés d’État chinoises détentrices du plus gros contrat minier de l’histoire de la RDC, a versé au moins 30 millions de dollars à la famille et au premier cercle de l’ancien président Joseph Kabila. Sa famille a aussi obtenu en secret des parts dans l’autoroute et le barrage liés à la mine.
par Yann Philippin et Sonia Rolley (RFI)
Journal — International
Des millions volés à l’État ont financé un retrait de cash par le directeur financier de Kabila
L’entreprise congolaise Egal, qui a détourné 43 millions de dollars de fonds publics en 2013, en a reversé 3,3 millions sur un compte de la présidence de la République de RDC afin de compenser un retrait d’espèces effectué par le directeur financier du président Joseph Kabila.
par Yann Philippin
Journal — International
Russie : pourquoi le Kremlin veut en finir avec Memorial
L’historien Nicolas Werth explique les enjeux de la possible dissolution, par la justice russe, de l’ONG Memorial. Celle-ci se consacre à documenter les crimes de la période soviétique, mettant ainsi des bâtons dans les roues du roman national poutinien.
par Antoine Perraud
Journal — France
Mosquée « pro-djihad » : au Conseil d’État, le ministère de l’intérieur se débat dans ses notes blanches
Vendredi 26 novembre, le Conseil d’État a examiné le référé de la mosquée d’Allonnes (Sarthe), qui conteste sa fermeture pour six mois ordonnée par arrêté préfectoral le 25 octobre. Devant les magistrats, la valeur de feuilles volantes sans en-tête, date ni signature, a semblé s’imposer face aux arguments étayés de la défense. Compte-rendu.
par Lou Syrah

La sélection du Club

Billet de blog
Avec le poids des morts
« Chaque famille, en Côte d'Ivoire, par exemple, est touchée. Tu vois le désastre, dans la mienne ? On assiste à une tragédie impensable ». C. témoigne : après un frère perdu en Libye, un neveu disparu en mer, il est allé reconnaître le corps de sa belle-sœur, dont le bateau a fait naufrage le 17 juin 2021 aux abords de Lanzarote, à Orzola.
par marie cosnay
Billet de blog
« Murs de papiers »
[Archive] Olivier Cousin, dans son dernier film, nous donne à voir ce qu’est la vie des sans-papiers à travers une permanence d’accueil de la Cimade : des chemins de l’exil aux mille dangers, des parcours du combattant face à une administration française kafkaïenne, la fin de la peur et l'espérance en une vie meilleure, apaisée.
Billet de blog
« L’Héroïque Lande - La Frontière brûle » : des vies électriques
[Archive] «L'Héroïque Lande. La Frontière brûle», réalisé par Elisabeth Perceval et Nicolas Klotz, renverse les attendus d'un film «sur» La Jungle de Calais, pour sonder les puissances politiques et sensibles du cinéma, avec des images qui s'imaginent depuis une Zone et avec ses fugitifs.
par Robert Bonamy
Billet de blog
« Atlantique », un film de Mati Diop
Des jeunes ouvriers au Sénégal ne sont pas payés depuis plusieurs mois rêvent de partir pour l’Europe au risque de leur vie. Ada, amoureuse de l’un de ces hommes, est promise à un riche mariage contre son gré. Les esprits auront-ils raison de ces injustices ?
par Cédric Lépine